-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the United States, ischemic stroke affects about 700,000 patients each year, and so far, there are no effective pharmacological preparations that can promote recovery
Experts studied the pharmacodynamics and pharmacokinetics of NTS-104/105 and used models of embolism and transient mid-cerebral artery occlusion to study the dose-related effects
Plasma and brain pharmacokinetic analysis showed that NTS-104 was rapidly converted to NTS-105, reached peak concentrations ≈ 1 hour after the administration, and distributed similarly
One study at a single dose level confirmed that administration of NTS-104 4 hours after transient mid-cerebral artery occlusion also had a neuroprotective effect
In summary, NTS-104 is a novel original drug that can be converted into a novel neuroactive steroid NTS-105, which can improve the functional results
References:
Pharmacological Characterization of a Novel Neuroactive Steroid Prodrug, NTS-104, and Its Neuroprotective Activity in Experimental Stroke Models.